Case
Published · Updated · 2 min read
Unintentional weight loss during fingolimod therapy: predominant adipose tissue loss in one case
What it means for practice
Consider body composition assessment and investigation of alternative causes for unexplained weight loss during fingolimod therapy. This case does not establish a causal relationship with the drug.
Summary
A case describes progressive unintentional weight loss in a 54-year-old man with relapsing-remitting multiple sclerosis during fingolimod therapy. The author notes that clinically significant weight loss during this treatment has rarely been characterized in detail, particularly regarding body composition changes.
Clinical course and findings
Over approximately 2 years, body weight decreased from 100 to 78 kg without appetite loss, dietary restriction, increased physical activity, or major lifestyle changes. Extensive multidisciplinary evaluation did not identify malignancy, chronic infection, gastrointestinal disease, endocrine abnormalities, or systemic inflammatory disorders.
Multifrequency bioelectrical impedance analysis showed low adipose tissue parameters with relative preservation of skeletal muscle mass and hydration status. This suggested that adipose tissue reduction may have represented a major component of the weight loss. Body weight remained stable during subsequent clinical follow-up.
Interpretation and limitations
The temporal relationship and exclusion of major alternative causes suggest a possible association with fingolimod that merits further investigation. However, a single observation cannot establish causality. The author highlights the potential value of body composition assessment for unexplained weight loss during this therapy.
Case analysis
- Likely mechanism
- Fingolimod is a sphingosine-1-phosphate receptor modulator. The abstract does not explain a mechanism for possible weight loss or predominant adipose tissue reduction; the body composition findings do not establish such a mechanism.
- Causality assessment
- Editorial WHO-UMC assessment: possible, based on the reported temporal relationship and the absence of identified major alternative causes. The abstract provides no formal author-reported causality assessment or information on fingolimod withdrawal and rechallenge; causality remains unproven.
- Take-home lesson
- Unexplained weight loss during fingolimod therapy warrants investigation of alternative causes. Body composition assessment may help characterize adipose tissue loss and muscle mass preservation, but does not itself establish drug causality.
Source
-
Can Usta N. Body Composition Findings During Weight Loss Observed in Fingolimod-Treated Relapsing-Remitting Multiple Sclerosis. Clin Neuropharmacol. 2026. doi:10.1097/WNF.0000000000000714
PubMed 42970463 DOI 10.1097/WNF.0000000000000714 Original: pubmed.ncbi.nlm.nih.gov
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
